https://news.abbvie.com/news/press-releases/therapeutic-area/neuroscience/ 神经科学 版权2022 en - us AbbVie新狗万平台活动闻中心 https://news.abbvie.com/news/press-releases/fda-approves-expanded-botox-onabotulinumtoxina-label-to-include-eight-new-muscles-to-treat-adults-with-upper-limb-spasticity.htm < p > < span class = " xn-location”>北芝加哥,病了。, July 29, 2021 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion of BOTOX^® to include eight new muscles for the treatment of upper limb spasticity in adults. The new muscles for treatment include additional muscles of the elbow and forearm (brachialis, brachioradialis, pronator teres, and pronator quadratus), as well as intrinsic hand muscles (lumbricals and interossei) and thumb muscles (flexor pollicis brevis and opponens pollicis). The label now includes the use of ultrasound as a muscle localization technique in adult spasticity.

12312年 星期四,2021年7月29日08:07:00 EST https://news.abbvie.com/news/press releases/abbvie - -现在-数据-从其领先-偏头痛组合- - 2021美国头痛——社会——唯有通过年度meeting.htm——科学 < p > < span class = " xn-location”>北芝加哥,病了。< / span >, < span class = " xn-chron " > 5月26日,2021年< / span > AbbVie从(NYSE: ABBV)今天宣布数据从其偏头痛投资组合将会在2021年美国头痛学会(AHS)年度科学会议,举行几乎<跨类= " xn-chron " > 6月3 - 6 < / span >。共有23个摘要,包括四个讲台演讲,将从广泛的共享研究跨AbbVie& # 39;偏头痛组合。< / p > 12282年 结婚,2021年5月26日08:05:00 EST https://news.abbvie.com/news/press releases/abbvie -现在-数据-在其强劲-神经科学组合- - 2021 -美国-学院神经-长-年度meeting.htm < p > < span class = " xn-location”>北芝加哥,病了。< / span >、<跨类= " xn-chron " > 4月7日,2021年< / span > AbbVie从(NYSE: ABBV)今天宣布其广阔的神经科学组合的最新数据将在2021年的美国神经学学院(长)年度会议,举行几乎从17-22 4月<跨类= " xn-chron " > < / span >。共有33个摘要,包括一个讲台演讲在临床试验期间全体会议和三个口头报告,将从广泛的共享在偏头痛的光谱研究,先进帕金森# 39;疾病和痉挛状态。< / p > 12264年 结婚,07年4月2021 08:04:00 EST https://news.abbvie.com/news/press-releases/us-fda-accepts-abbvies-new-drug-application-for-atogepant-for-preventive-treatment-migraine.htm < p > < span class = " xn-location”>北芝加哥,病了。< / span >, < span class = " xn-chron " > 3月30日2021年< / span > AbbVie从(NYSE: ABBV)今天宣布,美国食品和药物管理局(FDA)已接受其新药申请(NDA) atogepant,试验性口头管理降钙素相关基因肽(CGRP怎样)受体拮抗剂(gepant),对偏头痛的预防治疗成年人满足标准情景性偏头痛。在2021年第三季度末AbbVie预计监管决定。< / p > 12258年 星期二,2021年3月30日08:03:00 EST https://news.abbvie.com/news/press-releases/botox-onabotulinumtoxina-receives-fda-approval-for-pediatric-detrusor-overactivity-associated-with-neurologic-condition.htm < p > < span class = " xn-location”>北芝加哥,病了。< / span >, < span class = " xn-chron " > 2月。2021 < / span >,从爱力根,一个AbbVie (NYSE: ABBV)公司今天宣布,美国食品和药物管理局(FDA)批准了肉毒杆菌<一口> < < /一口>治疗逼尿肌过度活跃(膀胱肌肉)与神经系统相关条件在儿科患者5岁及以上有反应不足或不能容忍抗胆碱能药物。< / p > 12243年 结婚,在美国东部时间2021年2月10 08:02:00 https://news.abbvie.com/news/press releases/allergan -美学和爱力根-一个abbvie -公司- - - - - - -现在- 16 -神经毒素的研究摘要-跨多个治疗-和-化妆品迹象- - 2021 -虚拟conference.htm毒素 < p > < span class = " xn-location”>北芝加哥,病了。, Jan. 15, 2021 /PRNewswire/ -- Allergan Aesthetics and Allergan, an AbbVie company (NYSE: ABBV), announced today that scientific and clinical experts in the field of neurotoxins will present results from 16 abstracts spanning pre-clinical and clinical studies evaluating key safety and efficacy of BOTOX® (onabotulinumtoxinA) across multiple therapeutic and cosmetic indications. Data includes long-term immunogenicity rates across 10 therapeutic and aesthetic indications, analyses from the Adult Spasticity International Registry (ASPIRE) study and Cervical Dystonia Patient Registry for BOTOX® Efficacy (CD-PROBE), reviewing adherence to onabotulinumtoxinA treatment in patients with spasticity and efficacy and tolerability in patients with cervical dystonia, respectively. Also to be presented are data on incontinence product use and associated costs in patients with overactive bladder treated with onabotulinumtoxinA. Additionally, results from a randomized controlled clinical trial on the efficacy and safety of three active doses of onabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children and findings from a study on the safety, pharmacodynamic response and treatment satisfaction, with increasing doses of onabotulinumtoxinA in patients with moderate to severe dynamic glabellar lines will be presented. These data will be presented at the TOXINS 2021 Virtual Conference, organized by The International Neurotoxin Association (INA), January 16-17.

12238年 星期五,2021年1月15日09:01:00 EST https://news.abbvie.com/news/press - releases/abbvie -现在-新-数据-从- 15 -摘要- - 2020 -国际symposium.htm虚拟——偏头痛——信任 < p > < span class = " xn-location”>北芝加哥,病了。< / span >、<跨类= " xn-chron " > 10月。2020 < / span > AbbVie从(NYSE: ABBV)今天宣布,它将来自多个临床试验的结果,包括新的提前3期临床试验的数据,评估的有效性和安全性临床实验医学atogepant,一个口头管理降钙素相关基因肽(CGRP怎样)受体拮抗剂(gepant),预防偏头痛,在2020年的虚拟偏头痛信托国际研讨会(mti), <跨类= " xn-chron " > 10月3 - 9 < / span >。总共15个摘要将评估安全、功效,并影响病人和医疗保健系统的AbbVie& # 39;偏头痛治疗组合,包括BOTOX®(onabotulinumtoxinA)和UBRELVY® (ubrogepant)。< / p > 12192年 星期五,2020年10月02 08:10:00 EST https://news.abbvie.com/news/press-releases/abbvie-receives-orphan-drug-and-fast-track-designations-from-us-food-and-drug-administration-for-elezanumab-an-investigational-monoclonal-antibody-rgma-inhibitor-for-treatment-spinal-cord-injury.htm < p > < span class = " xn-location”>北芝加哥,病了。< / span >、<跨类= " xn-chron " > 9月。2020 < / span > AbbVie从(NYSE: ABBV)今天宣布,美国食品和药物管理局(FDA)批准孤儿药物和elezanumab快速通道名称(abt - 555),试验性治疗脊髓损伤后患者。< / p > 12189年 星期一,2020年9月28日08:09:00 EST https://news.abbvie.com/news/press-releases/abbvie-to-present-new-data-from-18-abstracts-at-international-congress-parkinsons-disease-and-movement-disorders.htm < p > < span class = " xn-location”>北芝加哥,病了。< / span >、<跨类= " xn-chron " > 9月。2020 < / span > AbbVie从(NYSE: ABBV)今天宣布,将目前的一些研究结果,包括DYSCOVER研究评估DUODOPA®的功效;(左旋多巴/卡比多巴肠凝胶)的持续时间和严重程度在晚期帕金森患者运动障碍# 39;疾病(PD),在2020年国际帕金森大会# 39;s Disorders®疾病和运动;虚拟国会,< span class = " xn-chron”> 9月12日至16日< / span >。总共18摘要将,包括概述关键的第三阶段研究设计的临床实验医学abbv - 951先进的PD患者,几项研究评估PD的经济负担,以及新的和更新的数据评估AbbVie& # 39;神经科学组合和管道。< / p > 12182年 星期五,2020年9月11日11:09:00 EST https://news.abbvie.com/news/press-releases/say-no-to-chronic-migraine-monday-urges-people-living-with-chronic-migraine-to-seek-help-from-headache-specialist.htm < p > < span class = " xn-location”>北芝加哥,病了。< / span >、<跨类= " xn-chron " > 8月。31, 2020 /PRNewswire/ -- Healthy living blogger Becca Ludlum knows all too well the physical and mental toll Chronic Migraine can have. She experienced self-described 'daily unbreaking migraine attacks.' Her story is more common than you think. In the U.S., more than 3.3 million adults live with Chronic Migraine¹, and people who experience the burden and disability of migraine disease wait on average four years before speaking with a healthcare professional.² The campaign 'Say No to Chronic Migraine Monday' urges people living with Chronic Migraine to make an appointment today with a headache specialist to discuss treatment options.

12176年 星期一,2020年8月31日08:08:00 EST https://news.abbvie.com/news/press-releases/abbvie-announces-serena-williams-as-spokesperson-to-shed-light-on-ubrelvy-ubrogepant-as-an-effective-treatment-option-for-migraine-attacks.htm <强>北芝加哥,病了。, – August 5, 2020 – AbbVie today announced Serena Williams as the spokesperson for UBRELVY® to raise awareness of an effective acute treatment option for people living with migraine. Whether at work, taking care of kids, or preparing for a Grand Slam Championship tennis match like Serena, UBRELVY can provide relief of migraine attacks. Unlike older migraine medicines that primarily work by constricting blood vessels after a migraine attack has already begun, UBRELVY is the first pill of its kind for the acute treatment of migraine to directly block a protein called CGRP (calcitonin gene-related peptide), which is believed to play a critical role in migraine attacks. Available by prescription since January 2020, UBRELVY is approved for the acute treatment of migraine with or without aura in adults. It is not indicated for the preventive treatment of migraine. 12170年 结婚,05年8月2020 18:10:00 EST https://news.abbvie.com/news/press-releases/abbvie-announces-positive-phase-3-data-for-atogepant-in-migraine-prevention.htm < p > < span class = " xn-location”>北芝加哥,病了。< / span >、<跨类= " xn-chron " > 7月29日,2020年< / span > AbbVie从(NYSE: ABBV)今天宣布,第三阶段推进试验评估临床实验医学atogepant,一个口头管理降钙素相关基因肽(CGRP怎样)受体拮抗剂的主要终点(gepant)达到统计上显著更大的月平均减少偏头痛的日子,与安慰剂相比,剂量在12周的治疗期。与这些结果,结合积极的2/3阶段试验之前,AbbVie计划继续推进监管提交<跨类= " xn-location " > < / span >美国和其他国家。完整的数据结果将会在即将到来的国会医疗和/或在同行评审的杂志上发表。< / p > 12166年 结婚,2020年7月29日08:07:00 EST https://news.abbvie.com/news/press-releases/fda-approves-expanded-botox-onabotulinumtoxina-label-for-treatment-pediatric-patients-with-spasticity.htm < p > < span class = " xn-location”>北芝加哥,病了。< / span >, < span class = " xn-chron " > 7月9日,2020年< / span >,从爱力根,一个AbbVie (NYSE: ABBV)公司今天宣布,美国食品和药物管理局(FDA)批准了一项补充生物制剂许可证应用(sBLA)支持扩大使用肉毒杆菌<一口> < < /一口>儿科患者的痉挛状态的治疗2岁及以上,包括那些与下肢痉挛状态导致的脑瘫。< / p > 12159年 星期四,09年7月2020 18:07:00 EST https://news.abbvie.com/news/press-releases/fda-accepts-supplemental-biologics-license-application-sbla-for-botox-onabotulinumtoxina-for-treatment-pediatric-patients-with-neurogenic-detrusor-overactivity.htm < p > < span class = " xn-location”>北芝加哥,病了。, June 22, 2020 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental biologics license application (sBLA) to expand the BOTOX^® prescribing information for the treatment of signs and symptoms of detrusor (bladder muscle) overactivity associated with an underlying neurologic condition (e.g., spina bifida, spinal cord injuries) in pediatric patients (5 -17 years of age) who have an inadequate response to, or are intolerant of, or for any reason unwilling to continue anticholinergic medication.

12154年 星期一,2020年6月22日08:06:00 EST https://news.abbvie.com/news/press releases/abbvie -展示虚拟- 2020 - 27 -研究- - - - - - - - -科学年会-美国-头痛——society.htm < p > < span class = " xn-location”>北芝加哥,病了。< / span >, < span class = " xn-chron " > 6月15日2020 < / span >,从AbbVie (NYSE: ABBV),研究全球生物制药公司,今天宣布它已经27个研究接受虚拟2020年度科学会议的美国头痛学会(AHS)。这些摘要突出了公司# 39;偏头痛持续的创新,包括其临床实验的产品,atogepant,同时加强BOTOX®的疗效和安全性配置文件;和UBRELVY™ . < / p > 12150年 星期一,2020年6月15日08:06:00 EST https://news.abbvie.com/news/press-releases/news-type/product-news/allergan-receives-us-fda-approval-for-ubrelvy-for-acute-treatment-migraine-with-or-without-aura-in-adults.htm <位置idsrc = " xmltag.org " value = "陆/ ie . .都柏林都柏林" > < /位置>,<时间> 12月。2019 < /时间>,从< org idsrc = " xmltag.org " value = " NYSE: AGN " >爱力根公司< / org > (NYSE:, AGN)今天宣布,美国<组织>食品和药物管理局(FDA) < / org >(<组织> FDA < / org >)已经批准了一种新药申请(NDA) UBRELVY™(ubrogepant)急性治疗成人偏头痛有或没有光环。UBRELVY™是第一个也是唯一通过降钙素相关基因肽(CGRP怎样)受体拮抗剂(gepant)治疗偏头痛发作,一旦他们开始。偏头痛是一种神经系统疾病,其特征是间歇性的偏头痛发作症状,往往失能。偏头痛折磨3100万美国人,是第三个最常见的疾病和第二世界残疾的主要原因。 12105年 星期一,2019年12月23日15:13:00 EST https://news.abbvie.com/news/press-releases/news-type/product-news/botox-onabotulinumtoxina-celebrates-30-years-endless-innovation.htm <位置idsrc = " xmltag.org " value = "陆/ ie . .都柏林都柏林" > < /位置>,<时间> 12月。2019 < /时间> /价值——< org idsrc = " xmltag.org " value = " NYSE: AGN " >爱力根公司< / org > (NYSE: AGN)是纪念今天的开始<一口> 30 th < /一口>周年庆典为肉毒杆菌<一口> << /一口>今年响of  <组织>纽约证交所< / org >开盘。在过去的30年里,超过1亿瓶的肉毒杆菌<一口> << /一口>和肉毒杆菌<一口> < < /一口>化妆品已经生产在世界范围内,提供一个可信和有效的治疗选择各种治疗和美学的用途。有两个额外的<组织>美国食品和药物管理局(FDA) < / org >(<组织> FDA < / org >)今年批准治疗小儿上肢痉挛状态的迹象和小儿下肢痉挛状态,排除痉挛状态造成脑瘫,肉毒杆菌<一口> << /一口>和肉毒杆菌<一口> << /一口>化妆品现在自豪地拥有14治疗和美学指标结合,加强科学领导的神经毒素。 12103年 星期一,2019年12月16日07:00:00 EST https://news.abbvie.com/news/press-releases/abbvie-and-scripps-research-announce-collaboration-to-develop-broad-range-new-therapeutics.htm < p > < span class = " xn-location”>北芝加哥,病了。< / span >和< span class = " xn-location”>拉霍亚加州。< / span >, < span class = " xn-chron " > 12月。9, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company and Scripps Research, an international leader in non-profit biomedical research and drug discovery, today announced a collaboration to develop new therapies for a range of diseases, including in the therapeutic areas of oncology, immunology, neurology and fibrosis.

11893年 星期一,2019年12月09 08:12:00 EST https://news.abbvie.com/news/press-releases/news-type/rd-news/allergan-announces-positive-phase-3-achieve-i-trial-results-for-ubrogepant-published-in-new-england-journal-medicine.htm <位置idsrc = " xmltag.org " value = "陆/ ie . .都柏林都柏林" > < /位置>,<时间> 12月。2019 < /时间> < b >,从< / b > < org idsrc = " xmltag.org " value = " NYSE: AGN " >爱力根公司< / org > (NYSE: AGN)今天宣布,从实现积极的结果我(UBR-MD-01),一个健壮的3期临床试验评估疗效,安全性和耐受性ubrogepant,已发表在《<时间> 12月5日< /时间> <一口> th < /一口> <我> <组织>问题新英格兰医学杂志》的< / org > < / I > (NEJM) <我>。< / i >发表的第二个关键的数据试验钢筋与ubrogepant偏头痛的急性治疗,与安慰剂相比,导致疼痛发生率显著更大的自由和自由从最麻烦的migraine-associated症状在2小时50毫克和100毫克剂量。如果FDA <组织> < / org >批准,ubrogepant将是第一个可用的和批准小分子,oral 降钙素相关基因肽(CGRP怎样)受体拮抗剂(gepant)急性治疗偏头痛。 12102年 2019年12月结婚,04 17:26:00 EST https://news.abbvie.com/news/press-releases/news-type/rd-news/allergan-announces-positive-phase-3-achieve-ii-trial-results-for-ubrogepant-published-in-journal-american-medical-association.htm <位置idsrc = " xmltag.org " value = "陆/ ie . .都柏林都柏林" > < /位置>,<时间> 11月。19日2019 < /时间> /价值/ < org idsrc = " xmltag.org " value = " NYSE: AGN " >爱力根公司< / org > (NYSE: AGN)今天宣布,从实现II (UBR-MD-02)积极的结果,一个关键的3期临床试验评估疗效,安全性和耐受性ubrogepant,已发表在《<时间> 11月19日< /时间> <一口> th < /一口> <我>问题<组织>美国医学协会的期刊< / org > < / i > (JAMA <我> < / i >) <我>。< / i >这些数据强化了急性治疗偏头痛ubrogepant与安慰剂比较导致疼痛发生率显著更大的自由在两小时50毫克和25毫克剂量,和自由从最麻烦的migraine-associated症状与50毫克剂量两个小时。If approved, ubrogepant would potentially be the first FDA-approved small molecule, oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the acute treatment of migraine. 12100年 星期二,2019年11月19日11:22:00 EST